‹ ›
MYP_164760
← PREVIOUS NEXT → BACK
Basic Information
LP-67
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
not Standard
21 amino acids
-
contains X representing unresolved or non-standard residue
Sequence
LLEQAEEQQKKNEEELKKLEX
Physicochemical Analysis
0.00 Da
0.00
0.00
0.00
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0008573 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
The 'X' at position 21 is Lys-C16(palmitic acid)
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells
0.003417±0.000419 μM
IC50
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. J Virol. 2018 Sep 26;92(20):e01088-18. doi: 10.1128/JVI.01088-18. PMID: 30089693. PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0017465 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
The 'X' at position 21 is Lys-C16(palmitic acid)
Bio-Activity Profile
Antimicrobial Antiviral
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. J Virol. 2018 Sep 26;92(20):e01088-18. doi: 10.1128/JVI.01088-18. PMID: 30089693. PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0025372 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
unspecified non-canonical residue at 21
Bio-Activity Profile
Antiviral
HIV-1 HxB2
PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0041022 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
unspecified non-canonical residue at 21
Bio-Activity Profile
Antiviral
HIV-1 NL4-3 PsV
PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0085212 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
The 'X' at position 21 is Lys-C16(palmitic acid)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 JRCSF | TZM-bl cells
0.001527±0.000565 μM
IC50
Mammalian: 5.5 h; Yeast: 3 min; E. coli: 2 min
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | Chong H, Zhu Y, Yu D, He Y. | J Virol. 2018 Sep 26;92(20):e01088-18. | DOI:10.1128/JVI.01088-18 | PMID:30089693 PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
1 2 NEXT LAST
Showing 5 records on this page · Page 1 of 2